ISRG - Intuitive Surgical, Inc.
Intuitive Surgical was an early leader in the surgical robotics space. The industry has developed, and now the company faces material competition from well-heeled competitors.
Both Intuitive Surgical and Stryker just posted their fifth straight earnings beat, and Wall Street is cheering for both. But a structural difference buried inside their business models quietly separates a compounder from a cyclical recovery story.
Intuitive Surgical's latest version of the da Vinci system could unlock important opportunities. Novo Nordisk is still well-positioned to cash in on the GLP-1 market.
Robotics is entering a new era as AI fuels humanoid adoption, with four ETFs offering diversified exposure to the sector's growth.
AXQ Capital LP increased its position in Intuitive Surgical, Inc. (NASDAQ: ISRG) by 301.1% in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 15,239 shares of the medical equipment provider's stock after purchasing an additional 11,440 shares during the quarter. Intuitive Surgical accounts
Tech giant Nvidia has remained ahead of rivals thanks to its competitive advantage. These healthcare companies have proven expertise in their fields -- and they would be difficult to unseat.
Intuitive Surgical dominates the robotic surgery market, and this has led to earnings growth over time. Some investors have worried about a slowdown in U.S. procedure growth in recent times.
Intuitive Surgical is boosting R&D despite macro headwinds, targeting AI, robotics and new procedures to expand its market and drive long-term growth.
In the most recent trading session, Intuitive Surgical, Inc. (ISRG) closed at $372.6, indicating a +1.51% shift from the previous trading day.
ISRG's record cash flow is fueling R&D, manufacturing expansion and over 100 da Vinci 5 updates, strengthening its innovation edge.
Intuitive Surgical leads surgical robotics with faster procedure growth and recurring revenue, while Medtronic offers a cheaper, diversified growth profile.
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
ISRG is expanding in Asia Pacific with a new Penang plant to boost capacity and support rising demand for robotic-assisted surgery.
Intuitive's revenue growth came in at 19% in its most recent quarter. The company's full-year guidance for procedures, however, was underwhelming and lower than the most recent quarter.
SpaceX seems promising, but the stock looks too expensive at current levels. Intuitive Surgical has lagged broader equities this year, but it's a great buy on the dip.
ISRG's software roadmap is strengthening da Vinci 5, with new features, renewals and recurring service revenues reinforcing its digital ecosystem.
Nvidia turns financier, CAVA's traffic sizzles, Berkshire ends its 3-year drought, and more
TBBB rallies on strong expansion, Anthropic could IPO with $2 trillion valuation, and more
ISRG's US procedure growth slows in Q2, but ACA-related care deferrals may prove temporary as underlying demand and da Vinci 5 adoption remain strong.
Intuitive Surgical is rated a Hold, with a modeled +9.17% upside and a price target of $426.65. ISRG's growth thesis centers on untapped ASC procedure volume, overstated remanufacturing risks, and remanufacturing's role in expanding the installed base. Remanufacturing currently poses a limited threat, with sub-3% penetration and approval for only 4 out of 45+ instruments.